Brent L. Iverson received his Ph.D. from Stanford University in 1982 and currently teaches at University of Texas, Austin. He is a distinguished teacher and respected researcher. Iverson's research group has developed methods for recombinant antibody or enzyme cloning and has directed its evolution. In collaboration with the Georgiou group, he pioneered a novel E. coli surface expression/FACS selection technology that has allowed the group to enhance antibody affinity.